Timmerman Philip, Herling Christian, Stoellner Daniela, Jaitner Birgit, Pihl Susanne, Elsby Karen, Henderson Neil, Barroso Begona, Fischmann Stephanie, Companjen Arjen, Versteilen Amanda, Bates Stewart, Kingsley Clare, Kunz Ulrich
Janssen Research & Development.
Bioanalysis. 2012 Aug;4(15):1883-94. doi: 10.4155/bio.12.164.
Biomarkers have become increasingly important in drug development and many bioanalysts are getting involved. Consequently, different views on how to approach the bioanalysis of biomarkers have been published or are being developed. The European Bioanalysis Forum has intensively discussed this topic since 2010 and is ready with their recommendation on method establishment and bioanalysis of biomarkers. Acknowledging that the challenges step outside the bioanalytical laboratory is a cornerstone of our recommendation. The importance of integrating all scientific aspects, from purely analytical aspects, all the way to understanding the biology and effects of the biomarker, prior to embarking on method establishment or sample analysis, cannot be underestimated. Close and iterative interactions with the teams requesting the data is imperative to develop a bioanalytical strategy that combines science, analytical performance and regulations. The European Bioanalysis Forum developed a straightforward decision tree to help the scientific community in developing a bioanalytical strategy for any biomarker in drug development.
生物标志物在药物研发中变得越来越重要,许多生物分析人员都参与其中。因此,关于如何进行生物标志物生物分析的不同观点已经发表或正在形成。自2010年以来,欧洲生物分析论坛一直在深入讨论这个话题,并准备好就生物标志物的方法建立和生物分析提出建议。认识到生物分析实验室之外的挑战是我们建议的基石。在着手建立方法或进行样品分析之前,整合所有科学方面,从纯粹的分析方面,一直到理解生物标志物的生物学特性和作用,其重要性不可低估。与要求提供数据的团队进行密切和反复的互动对于制定一个结合科学、分析性能和法规的生物分析策略至关重要。欧洲生物分析论坛开发了一个简单的决策树,以帮助科学界为药物研发中的任何生物标志物制定生物分析策略。